

Protocol

Autologous Platelet-Derived Growth Factors for Wound Healing and Other Non-Orthopedic Conditions

(20116)

Medical Benefit		Effective Date: 10/01/15	Next Review Date: 07/21
Preauthorization	No	Review Dates: 09/10, 07/11, 07/12, 05/13, 05/14, 05/15, 07/15, 07/16, 07/17, 07/18, 07/19, 07/20	

Preauthorization is not required.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

RELATED PROTOCOLS

Bioengineered Skin and Soft Tissue Substitutes

Electrostimulation and Electromagnetic Therapy for Treating Wounds

Negative Pressure Wound Therapy in the Outpatient Setting

Orthopedic Applications of Platelet-Rich Plasma

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none">• With chronic wounds	Interventions of interest are: <ul style="list-style-type: none">• Platelet-rich plasma	Comparators of interest are: <ul style="list-style-type: none">• Standard wound care	Relevant outcomes include: <ul style="list-style-type: none">• Symptoms• Change in disease status• Morbid events• Quality of life• Treatment-related morbidity
Individuals: <ul style="list-style-type: none">• With acute surgical or traumatic wounds	Interventions of interest are: <ul style="list-style-type: none">• Platelet-rich plasma	Comparators of interest are: <ul style="list-style-type: none">• Standard wound care	Relevant outcomes include: <ul style="list-style-type: none">• Symptoms• Change in disease status• Morbid events• Quality of life• Treatment-related morbidity

DESCRIPTION

The use of blood-derived growth factors, including recombinant platelet-derived growth factors (PDGFs) and platelet-rich plasma (PRP), has been suggested as a treatment for wounds or other miscellaneous non-orthopedic conditions, including but not limited to, diabetic ulcers, pressure ulcers, venous stasis ulcers, and surgical and traumatic wounds.

SUMMARY OF EVIDENCE

RECOMBINANT PDGFS

For individuals who have diabetic lower-extremity ulcers who receive recombinant PDGF, the evidence includes RCTs and systematic reviews. The relevant outcomes are symptoms, change in disease status, morbid events, quality of life (QOL), and treatment-related morbidity. Results have shown improved rates of healing with use of recombinant PDGF for diabetic neuropathic ulcers and pressure ulcers. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have pressure ulcers who receive recombinant PDGF, the evidence includes RCTs and systematic reviews. The relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. Results have shown improved rates of healing with use of recombinant PDGF for pressure ulcers. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have venous stasis leg ulcers or acute surgical or traumatic wounds who receive recombinant PDGF, the evidence includes small RCTs. The relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. The level of evidence does not permit conclusions whether recombinant PDGF is effective in treating other wound types, including chronic venous ulcers or acute traumatic wounds. The evidence is insufficient to determine the effects of the technology on health outcomes.

PLATELET-RICH PLASMA

For individuals who have chronic wounds or acute surgical or traumatic wounds who receive PRP, the evidence includes meta-analyses of a number of small controlled trials. The relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. Current results of trials using PRP are mixed, and the studies are limited in both size and quality. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have chronic wounds who receive PRP, the evidence includes a number of small controlled trials. The relevant outcomes are symptoms, change in disease status, morbid events, QOL, and treatment-related morbidity. Current results of trials using PRP are mixed and the studies are limited in both size and quality. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Use of platelet-rich plasma (i.e., autologous blood-derived preparations) is considered **investigational** for the treatment of acute or chronic wounds, including surgical wounds and nonhealing ulcers.

POLICY GUIDELINES

Note: This protocol does not address becaplermin.

MEDICARE ADVANTAGE

For Medicare Advantage members there may be potential for benefit under coverage with evidence development (CED).

BACKGROUND

WOUND HEALING TREATMENT

A variety of growth factors have been found to play a role in wound healing, including platelet-derived growth factor (PDGF), epidermal growth factor, fibroblast growth factors, transforming growth factors, and insulin-like growth factors. Autologous platelets are a rich source of PDGF, transforming growth factors (that function as a mitogen for fibroblasts, smooth muscle cells, and osteoblasts), and vascular endothelial growth factors. Recombinant PDGF also has been extensively investigated for clinical use in wound healing.

Autologous platelet concentrate suspended in plasma, also known as platelet-rich plasma (PRP), can be prepared from samples of centrifuged autologous blood. Exposure to a solution of thrombin and calcium chloride degranulates platelets, releasing various growth factors, and results in the polymerization of fibrin from fibrinogen, creating a platelet gel. The platelet gel can then be applied to wounds or may be used as an adjunct to surgery to promote hemostasis and accelerate healing. In the operating room setting, PRP has been investigated as an adjunct to a variety of periodontal, reconstructive, and orthopedic procedures. For example, bone morphogenetic proteins are a transforming growth factor, and thus PRP has been used in conjunction with bone-replacement grafting (using either autologous grafts or bovine-derived xenograft) in periodontal and maxillofacial surgeries.

PRP is distinguished from fibrin glues or sealants, which have been used for many years as a surgical adjunct to promote local hemostasis at incision sites. Fibrin glue is created from platelet-poor plasma and consists primarily of fibrinogen. Commercial fibrin glues are created from pooled homologous human donors; Tisseel® (Baxter International) and Hemaseel® (Haemacure Corp.) are examples of commercially available fibrin sealants. Autologous fibrin sealants can also be created from platelet-poor plasma. This protocol does not address the use of fibrin sealants.

Wound Closure Outcomes

This protocol addresses the use of PRP for non-orthopedic indications, which include a number of wound closure-related indications.

For this review, the primary endpoints of interest for the study of wound closure are as follows, consistent with guidance from the FDA for the industry in developing products for the treatment of chronic cutaneous ulcer and burn wounds¹:

1. Incidence of complete wound closure;
2. Time to complete wound closure (reflecting accelerated wound closure);
3. Incidence of complete wound closure following surgical wound closure;
4. Pain control.

REGULATORY STATUS

PLATELET-RICH PLASMA

The FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, Title 21, parts 1270 and 1271. Blood products such as PRP are included in these regulations.

Under these regulations, certain products including blood products such as PRP are exempt and therefore, do not follow the traditional FDA regulatory pathway. To date, the FDA has not attempted to regulate activated PRP.²

Numerous PRP preparation systems have been cleared for marketing by the FDA through the 510(k) process. These devices are intended to concentrate patient plasma at the point of care during bone grafting procedures. The use of different devices and procedures can lead to variable concentrations of active platelets and associated proteins, increasing variability between studies of clinical efficacy.

In 2018, the “Boxed Warning” and “Warnings and Precautions” were changed to remove “increased rate of cancer mortality” and “cancer mortality,” respectively.

Services that are the subject of a clinical trial do not meet our Technology Assessment and Medically Necessary Services Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment and Medically Necessary Services Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. U.S. Food and Drug Administration. Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment. Rockville, MD: Food and Drug Administration; 2006 June.
2. U.S. Food and Drug Administration (FDA). Tissue and Tissue Products. 2016; <http://www.fda.gov/BiologicsBloodVaccines/TissueTissueProducts/>. Accessed November 21, 2019.
3. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Becaplermin for wound healing. TEC Assessments. 1999;Volume 14:Tab 5.
4. Crovetti G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic wounds. *Transfus Apher Sci*. Apr 2004;30(2):145-151. PMID 15062754
5. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. *Plast Reconstr Surg*. Nov 2004;114(6):1502-1508. PMID 15509939
6. Kevy SV, Jacobson MS. Comparison of methods for point of care preparation of autologous platelet gel. *J Extra Corpor Technol*. Mar 2004;36(1):28-35. PMID 15095838
7. Castillo TN, Pouliot MA, Kim HJ, et al. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. *Am J Sports Med*. Feb 2011;39(2):266-271. PMID 21051428
8. Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateltex and one manual procedure. *Vox Sang*. Aug 2009;97(2):110-118. PMID 19392780
9. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Growth factors for wound healing. TEC Evaluations. 1992;7:352-377.

10. Zhao XH, Gu HF, Xu ZR, et al. Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis. *Metabolism*. Oct 2014; 63(10):1304-1313. PMID 25060693 NonOrthopedic Conditions
11. Margolis DJ, Bartus C, Hoffstad O, et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. *Wound Repair Regen*. Nov-Dec 2005;13(6):531-536. PMID 16283867
12. Sridharan K SG. Growth factors for diabetic foot ulcers: mixed treatment comparison analysis of randomized clinical trials. *Br J Clin Pharmacol*. 2018 Mar;84(3):434-444. doi: 10.1111/bcp.13470. Epub 2018 Jan 5. PMID: 29148070
13. Rees RS, Robson MC, Smiell JM, et al. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. *Wound Repair Regen*. May-Jun 1999;7(3):141-147. PMID 10417749
14. Senet P, Vicaut E, Beneton N, et al. Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial. *Arch Dermatol*. Aug 2011;147(8):926-930. PMID 21482863
15. Freedman BM, Oplinger EH, Freedman IS. Topical becaplermin improves outcomes in work related fingertip injuries. *J Trauma*. Oct 2005;59(4):965-968. PMID 16374289
16. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev*. Oct 17 2012;10:CD006899. PMID 23076929
17. Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev*. May 25 2016(5):CD006899. PMID 27223580
18. Martinez-Zapata MJ, Marti-Carvajal A, Sola I, et al. Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: a systematic review. *Transfusion*. Jan 2009;49(1):44-56. PMID 18954394
19. Carter MJ, Fylling CP, Parnell LK. Use of platelet-rich plasma gel on wound healing: a systematic review and meta-analysis. *Eplasty*. Oct 2011;11:e38. PMID 22028946
20. Picard F, Hersant B, Bosc R, et al. The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: A review and a proposal for a new standard care. *Wound Repair Regen*. Sep 2015;23(5): 638-643. PMID 26019054
21. Escamilla Cardenosa M, Dominguez-Maldonado G, Cordoba-Fernandez A. Efficacy and safety of the use of platelet-rich plasma to manage venous ulcers. *J Tissue Viability*. 2017 May;26(2):138-143. PMID 27955807
22. Del Pino-Sedeno T, Trujillo-Martin MM, Andia I, et al. Platelet-rich plasma for the treatment of diabetic foot ulcers: A meta-analysis. *Wound Repair Regen*, 2018 Dec 24;27(2). PMID 30575212
23. Li Y, Gao Y, Gao Y, et al. Autologous platelet-rich gel treatment for diabetic chronic cutaneous ulcers: A meta-analysis of randomized controlled trials. *J Diabetes*, 2018 Sep 6;11(5). PMID 30182534
24. Zhou SF, Estrera AL, Loubser P, et al. Autologous platelet-rich plasma reduces transfusions during ascending aortic arch repair: a prospective, randomized, controlled trial. *Ann Thorac Surg*. Apr 2015;99(4):1282-1290. PMID 25661906
25. Serraino GF, Dominijanni A, Jiritano F, et al. Platelet-rich plasma inside the sternotomy wound reduces the incidence of sternal wound infections. *Int Wound J*. Jun 2015;12(3):260-264. PMID 23692143
26. El-Anwar MW, Nofal AA, Khalifa M, et al. Use of autologous platelet-rich plasma in complete cleft palate repair. *Laryngoscope*. Jul 2016;126(7):1524-1528. PMID 27075516
27. Sidman JD, Lander TA, Finkelstein M. Platelet-rich plasma for pediatric tonsillectomy patients. *Laryngoscope*. Oct 2008;118(10):1765-1767. PMID 18622315
28. Almdahl SM, Veel T, Halvorsen P, et al. Randomized prospective trial of saphenous vein harvest site infection after wound closure with and without topical application of autologous platelet-rich plasma. *Eur J Cardiothorac Surg*. Jan 2011;39(1):44-48. PMID 20634084
29. Alamdari DH AM, Rahim AN, et al. Efficacy and Safety of Pleurodesis Using Platelet-Rich Plasma and Fibrin Glue in Management of Postoperative Chylothorax After Esophagectomy. *World J Surg*. 2018;42(4):1046-1055. PMID: 28986682

30. Kazakos K, Lyras DN, Verettas D, et al. The use of autologous PRP gel as an aid in the management of acute trauma wounds. *Injury*. Aug 2009;40(8):801-805. PMID 18703188
31. Marck RE, Gardien KL, Stekelenburg CM, et al. The application of platelet-rich plasma in the treatment of deep dermal burns: A randomized, double-blind, intra-patient controlled study. *Wound Repair Regen*. Jul 2016;24(4):712-720. PMID 27169627
32. Yeung CY HP, Wei LG, Hsia LC, Dai LG, Fu KY, Dai NT. Efficacy of Lyophilised Platelet-Rich Plasma Powder on Healing Rate in Patients With Deep Second Degree Burn Injury: A Prospective Double-Blind Randomized Clinical Trial. *Ann Plast Surg*. 2018 Feb;80(2S Suppl 1):S66-S69. PMID: 29369904.
33. Qaseem A, Humphrey LL, Forciea MA, et al. Treatment of pressure ulcers: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. Mar 03 2015;162(5):370-379. PMID 25732279
34. Association for the Advancement of Wound Care (AAWC). Guideline of Pressure Ulcer Guidelines. Malvern, PA: AAWC; 2010.
35. Association for the Advancement of Wound Care (AAWC). International Consolidated Venous Ulcer Guideline (ICVUG). 2015; <https://aawconline.memberclicks.net/assets/appendix%20c%20guideline%20icvug-textformatrecommendations-final%20v42%20changessaved18aug17.pdf>. Accessed November 21, 2019.
36. National Institute for Health and Clinical Excellence (NICE). Diabetic foot problems: prevention and management [NG19]. 2016; <https://www.nice.org.uk/guidance/ng19>. Accessed November 21, 2019.
37. National coverage determination (NCD) for blood-derived products for chronic non-healing wounds (270.3). Centers for Medicare and Medicaid Services. Effective date of version August 2, 2012. <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=217&ncdver=5&NCAId=260&bc=ACAAAAAAQAAA&>. Accessed November 13, 2019.
38. Centers for Medicare & Medicaid Services. Decision Memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R3). 2012; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=260>. Accessed December 23, 2019.
39. Centers for Medicare & Medicaid Services (CMS). CMS Manual System: Pub 100-3 Medicare National Coverage Determinations (Transmittal 127). 2010 Oct; <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R127NCD.pdf>. Accessed November 21, 2019.
40. Centers for Medicare & Medicaid Services. Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds (CAG-00190R2). 2008; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=208&bc=ACAAAAAAQCAA&>. Accessed November 21, 2019.